tiprankstipranks
Janux Therapeutics Inc (JANX)
NASDAQ:JANX
US Market
JANX
Janux Therapeutics Inc
RESEARCH TOOLSreports
Want to see JANX full AI Analyst Report?

Janux Therapeutics Inc (JANX) Stock News & Sentiment

716 Followers
Janux Therapeutics Adjusts Board Class Structure for Director
Premium
Company Announcements
Janux Therapeutics Adjusts Board Class Structure for Director
1d ago
8K
JANX
Janux’s JANX011 First‑in‑Human Study: Early Safety Readout Could Shape Autoimmune Upside
Premium
Company Announcements
Janux’s JANX011 First‑in‑Human Study: Early Safety Readout Could Shape Autoimmune Upside
7d ago
JANX
Advancing PSMA Franchise and Validating TRACTr Platform Underpin Buy Rating on Janux Therapeutics
Premium
Ratings
Advancing PSMA Franchise and Validating TRACTr Platform Underpin Buy Rating on Janux Therapeutics
8d ago
JANX
Maintained Buy on Janux: Confidence in Lead Asset JANX007 and Strategic Expansion of PSMA Prostate Cancer Franchise
Premium
Ratings
Maintained Buy on Janux: Confidence in Lead Asset JANX007 and Strategic Expansion of PSMA Prostate Cancer Franchise
13d ago
JANX
Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating
Premium
Ratings
Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating
2M ago
JANX
Janux: Encouraging Early T Cell Engager Data, Broad Pipeline, and Strong Cash Runway Support Buy Rating
Premium
Ratings
Janux: Encouraging Early T Cell Engager Data, Broad Pipeline, and Strong Cash Runway Support Buy Rating
2M ago
JANX
Janux Therapeutics: Rebuilding Confidence After JANX007 Setback with 2026 Clinical Catalysts and Validated PSMA x CD3 Platform
Premium
Ratings
Janux Therapeutics: Rebuilding Confidence After JANX007 Setback with 2026 Clinical Catalysts and Validated PSMA x CD3 Platform
2M ago
JANX
More JANX News >

JANX News on the Web

Maintained Buy on Janux: Confidence in Lead Asset JANX007 and Strategic Expansion of PSMA Prostate Cancer Franchise
TipRanks News
Bullish
Janux Therapeutics says first patient dosed in Phase 1 study of JANX014
TipRanks News
Bullish
Janux Therapeutics downgraded to Neutral from Buy at UBS
TipRanks News
Neutral
Janux Therapeutics price target lowered to $23 from $25 at Evercore ISI
TipRanks News
Bearish
JonesTrading Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)
TipRanks News
Bullish
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
Zacks
Bullish
Janux announces development candidate nomination under Bristol Myers collab
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Veeva Systems (VEEV) and Janux Therapeutics Inc (JANX)
TipRanks News
Bullish

News Score - Last 7 Days

Positive
JANX
Sector Average
Media Buzz
This Week3 articles
Weekly Average1 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is JANX’s Media Buzz Sentiment?
3 articles about JANX were published this week. In an average week, 1 articles are published.
    What is JANX’s weekly average amount of articles?
    In an average week, 1 articles about JANX are published.
      What is JANX’s News Sentiment?
      100% of articles about JANX were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week